Supercharged donor cells take aim at blood cancers

NCT ID NCT02494167

Ongoing Disease control Sponsor: Baylor College of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-phase trial tests whether specially trained immune cells from a donor can safely target and kill cancer cells in people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after a stem cell transplant. The cells are grown in a lab to recognize four proteins common on these cancer cells. The main goal is to find the safest dose and see if the cells can reduce or control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: donor-derived T cells trained to recognize tumor proteins (WT1, NY-ESO-1, PRAME, Survivin)
What this could lead to: If it works, this could offer a new way to control AML or MDS after a stem cell transplant, potentially reducing the risk of relapse.
What could go wrong: This is an early Phase 1 trial with only 44 participants, so safety and effectiveness are not yet proven. The treatment may cause side effects or fail to shrink the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia myelodysplastic syndrome Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA MYELODYSPLASTIC SYNDROME

Contacts and locations

Locations

Houston Methodist Hospital

Houston, Texas, 77030, United States
Texas Children's Hospital

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.